Does Inmode Ltd (NASDAQ:INMD) warrant a purchase right now? What to Consider Before Making a Decision

The stock of Inmode Ltd (NASDAQ:INMD) last traded at $19.99, up 1.58% from the previous session.

Data from the available sources indicates that Inmode Ltd (NASDAQ:INMD) is covered by 6 analysts. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $54.00 and a low of $22.00, we find $32.00. Given the previous closing price of $19.68, this indicates a potential upside of 62.6 percent. INMD stock price is now -29.95% away from the 50-day moving average and -41.95% away from the 200-day moving average. The market capitalization of the company currently stands at $1.66B.

In total, 3 analysts have assigned it a hold rating, and 1 have given it a buy rating. Brokers who have rated the stock have averaged $35.40 as their price target over the next twelve months.

With the price target reduced from $52 to $24, UBS Downgraded its rating from Buy to Neutral for Inmode Ltd (NASDAQ: INMD).

A total of 7.82% of the company’s stock is owned by insiders.

During the past 12 months, Inmode Ltd has had a low of $18.57 and a high of $48.25. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 12.51, and a quick ratio of 11.87. According to the stock market information, the enterprise value for the company is $1.03B, which is based on a 9.51 price-to-earnings ratio, a 0.69 price-to-earnings-growth ratio, and a beta of 2.23. The fifty day moving average price for INMD is $28.54 and a two-hundred day moving average price translates $34.44 for the stock.

The latest earnings results from Inmode Ltd (NASDAQ: INMD) was released for Sep, 2023. According to the Medical Devices Company, earnings per share came in at $0.72, beating analysts’ expectations of $0.64 by 0.08. This compares to $0.58 EPS in the same period last year. The net profit margin was 36.18% and return on equity was 29.30% for INMD. The company reported revenue of $123.11 million for the quarter, compared to $121.23 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 1.55 percent. For the current quarter, analysts expect INMD to generate $132.26M in revenue.

Inmode Ltd(INMD) Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women’s health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.

Related Posts